预约演示
更新于：2025-01-23
Simvastatin
辛伐他汀
更新于：2025-01-23
概要
基本信息
简介辛伐他汀是一种小分子实体，作为 HMG-CoA 还原酶抑制剂起作用，它负责肝组织中胆固醇的合成。 它被归类为 HMG-CoA 还原酶抑制剂或他汀类药物，可治疗由胆固醇水平升高引起的各种疾病。 辛伐他汀的有效适应症包括杂合子家族性高胆固醇血症、V 型高脂蛋白血症、中风、高脂血症和 II 型高脂蛋白血症。 Merck Sharp & Dohme Corp. 最初合成了辛伐他汀，并于 1988 年首次获准用于临床。尽管它被普遍使用，但辛伐他汀可能会引起一系列副作用，例如肌痛和肝毒性，患者应寻求咨询 在开始摄入之前从他们的医生那里获得。 |
药物类型 小分子化药 |
别名 Simvastatin (JP17/USP/INN)、Simvastatin for Suspension、Simvastatin Unlubricated Granulation + [44] |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂) |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (1991-09-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H38O5 |
InChIKeyRYMZZMVNJRMUDD-HGQWONQESA-N |
CAS号79902-63-9 |
关联
638
项与 辛伐他汀 相关的临床试验NCT06785727
StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial
CTRI/2024/10/074804
Comparison of the effect of Simvastatin impregnated gel foam and Platelet rich Fibrin on post-operative outcomes in patients undergoing extraction of mandibular molars - nil
IRCT20171015036782N10
Comparison of the quality of formed bone and pain after use of platelet rich fibrin (PRF) and Simvastatin in the extracted tooth socket
100 项与 辛伐他汀 相关的临床结果
登录后查看更多信息
100 项与 辛伐他汀 相关的转化医学
登录后查看更多信息
100 项与 辛伐他汀 相关的专利（医药）
登录后查看更多信息
11,307
项与 辛伐他汀 相关的文献（医药）2025-03-01REPRODUCTIVE TOXICOLOGY
Embryotoxicity of statins and other prescribed drugs with reported off-target effects on cholesterol biosynthesis
Article
作者: White, Kaylei ; Ramirez, Daniel ; Hartley, Taryn ; Abdulsalam, Zeenat ; Abdelmagid, Hagir ; Mansion, Aliyah ; Tadjuidje, Emmanuel ; Howe, Emily
Cholesterol plays pivotal cellular functions ranging from maintaining membrane fluidity to regulating cell-cell signaling. High cholesterol causes cardiovascular diseases, low cholesterol is linked to neuropsychiatric disorders, and inborn errors of cholesterol synthesis cause multisystem malformation syndromes. Statins lower cholesterol levels by inhibiting the first, rate-limiting reaction of the cholesterol biosynthesis pathway catalyzed by hydroxymethyl-glutaryl-Coenzyme A reductase (HMGCR). However, they have also been shown to interfere with cellular pathways that are unrelated to cholesterol synthesis. One of the last enzymes of cholesterol biosynthesis, 7-dehydrocholesterol reductase (DHCR7), is often mutated in the Smith-Lemli-Opitz syndrome (SLOS), a multisystem malformation syndrome. Strikingly, recent studies have shown that some prescribed psychotropic pharmaceuticals inhibit its activity. In this study, we used Xenopus laevis as a model organism to test the effects of 8 FDA-approved statins and selected prescribed psychotropic drugs on the developing vertebrate embryo. Drugs were tested at concentrations ranging from 0.1 µM to 50 µM. Embryos were exposed to the drugs from the blastula stage through the swimming tadpole stage with daily medium change. Our data show that statins are heterogenous with respect to their ability to cause embryonic lethality, with simvastatin, pitavastatin, lovastatin, cerivastatin, and fluvastatin being the most toxic ones. Observed phenotypes included delayed development, shortened body axis and pericardiac edema. On the other hand, psychotropic drugs were less embryonic lethal than statins but caused similar phenotypes as well as microcephaly and holoprosencephaly. Our findings suggest that the proximal and distal inhibition of cholesterol biosynthesis have different but overlapping effects on embryonic development.
2025-02-01BIOCHEMICAL PHARMACOLOGY
Hyperlipidemia impairs bone repair and regeneration via miR-193a-3p/STMN1/PI3K/Akt axis
Article
作者: Gui, Houda ; Zhu, Tiantian ; Liu, Chenghang ; Li, Zechuan ; Wang, Wenhao ; Li, Chuanhua ; Ren, Huiping ; Wang, Xi ; Ma, Anquan ; Sun, Baiyu ; Lan, Jing ; Shang, Jiaming ; Wang, Zhifeng ; Ma, Gaoqiang
Hyperlipidemia, a metabolic disease characterized by excessive blood lipid, disturbs bone metabolism by shifting cell fate of bone marrow stromal cells (BMSCs) towards adipogenic differentiation, thus resulting in poor bone regeneration and osseointegration of implants. Among numerous factors affecting hyperlipidemic bone metabolism, non-coding RNAs play an essential role in post-transcriptional regulation. Our previous study has shown that miR-193a-3p levels were elevated in hyperlipidemia, which hindered implant osseointegration and BMSCs function. However, the downstream targets and pathways of miR-193a-3p warrant further investigation. In this study, we identified STMN1 as the target of miR-193a-3p by miRNA databases and validated their interaction through dual luciferase reporter assays. Models of hyperlipidemia were established in vitro using a high-fat medium and in vivo with a high-fat diet to study these molecular interactions. Besides, miRNA array and PCR analyses confirmed the level of miR-193a and STMN1 in both rats with hyperlipidemia and high-fat-cultured BMSCs. Calvarial defects were used to evaluate STMN1's impact on bone repair and regeneration. As a result, miR-193a-3p levels were highly elevated in hyperlipidemic conditions, whereas the STMN1 levels were reduced sharply. The elevated miR-193a targeted STMN1 and disabled it from activating the PI3K/Akt pathway, thus resulting in delayed bone repair and poor bone regeneration. Additionally, common lipid-lowering drug simvastatin blunted hyperlipidemia's adverse effect on this axis. Our findings underscore the miR-193a-3p/STMN1/PI3K/Akt axis as a novel and promising therapeutic target for hyperlipidemic osteopenia, offering insights into the molecular mechanisms underlying bone metabolism disorders in hyperlipidemia and paving the way for innovative treatments.
2025-02-01CLINICAL NEUROLOGY AND NEUROSURGERY
Effect of prior use of statins on endovascular thrombectomy outcomes in acute ischemic stroke
Article
作者: Al-Mufti, Fawaz ; El Seblani, Nader ; Nagaraja, Nandakumar ; Kalra, Saurabh ; Kalra, Deepak
INTRODUCTION:
Acute large vessel occlusions (LVOs) account for up to one-third of acute ischemic strokes (AIS) and are associated with high mortality and severe functional deficits. Animal model research suggests that statins may have a protective effect on vessel wall injury during endovascular thrombectomy (EVT). We conducted a retrospective observational study to assess the impact of statin use on clinical outcomes post-EVT in AIS patients with LVOs.
METHODS:
Using the Global Collaborative Network consisting of about 143 million patients in TriNetX database, we identified adult AIS patients who underwent EVT between 2018 and 2023. Patients were categorized based on any statin use (atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, or pitavastatin) in the 3 months before AIS admission. The primary outcome was all-cause mortality at one-week post-EVT. Secondary outcomes included intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), decompressive hemicraniectomy procedure (DHC), and aspiration pneumonia at one-week post-EVT. Propensity score matching balanced relevant medical history, stroke severity, medications, and demographics. Cox proportional hazard regression analysis compared outcomes between statin and non-statin cohorts.
RESULTS:
We identified 17,774 patients who received EVT for LVO ischemic stroke. A total of 10,678 patients were on statins during 3 months prior to EVT and 7096 patients were not on statins. After 1:1 propensity matching, 2148 patients were included in each group. AIS patients treated with EVT and on statins had lower risk of all-cause mortality [7 % vs. 17 %; HR 0.43, 95 % CI 0.35-0.51], ICH [10 % vs. 15 %; HR 0.64, 95 % CI 0.51-0.74], SAH [3 % vs. 6 %; HR 0.48, 95 % CI 0.35-0.64], and aspiration pneumonia [4 % vs 8 %; HR 0.53, 95 % CI 0.41-0.70] compared to AIS patients treated with EVT but not on statins. Rates of DHC were similar between groups [2 % vs 2 %; HR 0.81; 95 % CI (0.52,1.25)].
CONCLUSION:
Statin use within 3 months prior to AIS was associated with better survival and lesser intracranial bleeding risks and complications following EVT. Future studies may help examine how the duration or dosages of statins or LDL levels on admission affect outcomes in LVO strokes treated with EVT.
100 项与 辛伐他汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| V型高脂蛋白血症 | 中国 | 1997-01-01 | |
| 冠状动脉疾病 | 美国 | 1991-12-23 | |
| 高脂血症 | 日本 | 1991-10-04 | |
| II型高脂蛋白血症 | 日本 | 1991-10-04 | |
| 冠心病 | 澳大利亚 | 1991-09-12 | |
| 杂合子家族性高胆固醇血症 | 澳大利亚 | 1991-09-12 | |
| 高胆固醇血症 | 澳大利亚 | 1991-09-12 | |
| 脑卒中 | 澳大利亚 | 1991-09-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高胆固醇血症 | 临床3期 | - | 2007-07-01 | |
| 家族性混合型高脂血症 | 临床3期 | - | 2006-01-24 | |
| 合并高脂血症 | 临床3期 | - | 2002-05-01 | |
| 纯合子家族性高胆固醇血症 | 临床3期 | - | 2000-05-03 | |
| 急性冠状动脉综合征 | 临床3期 | - | 1999-11-01 | |
| 胸痛 | 临床3期 | - | 1999-11-01 | |
| 心肌梗塞 | 临床3期 | - | 1999-11-01 | |
| 心血管疾病 | 临床3期 | 英国 | 1998-07-01 | |
| 颈动脉疾病 | 临床2期 | - | 2009-04-01 | |
| 1型糖尿病 | 临床2期 | 美国 | 2007-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 直肠癌 新辅助 | 135 | 範艱製積遞壓遞鹽鑰夢(衊衊獵築壓積願蓋憲鑰) = 壓鬱鏇窪糧範願願繭糧 廠繭夢夢襯廠積淵夢廠 (獵獵鹹艱壓餘醖製製壓 ) 更多 | 积极 | 2025-01-23 | ||
Placebo | 範艱製積遞壓遞鹽鑰夢(衊衊獵築壓積願蓋憲鑰) = 夢壓淵夢淵餘獵築廠構 廠繭夢夢襯廠積淵夢廠 (獵獵鹹艱壓餘醖製製壓 ) 更多 | ||||||
N/A | 38 | (Conventional pulpectomy) | 獵獵顧醖簾襯鏇獵廠醖(襯夢衊積築醖憲鬱鬱淵) = 壓範願淵願廠觸構築餘 糧築簾簾積憲網糧餘獵 (積鹽範廠積範齋鑰壓願 ) | 积极 | 2024-04-01 | ||
Non-instrumentation endodontic treatment (NIET) using 3Mixtatin | 獵獵顧醖簾襯鏇獵廠醖(襯夢衊積築醖憲鬱鬱淵) = 獵築窪糧壓選鹽範網醖 糧築簾簾積憲網糧餘獵 (積鹽範廠積範齋鑰壓願 ) | ||||||
临床4期 | 10 | (Simvastatin) | 衊獵範願壓構廠築窪顧(憲夢糧蓋簾選簾鑰鑰餘) = 築襯觸鹹餘鑰壓壓窪淵 顧憲襯醖鬱顧餘願選獵 (餘製觸遞衊觸鏇夢選襯, 遞衊製鹹製窪觸齋齋築 ~ 鏇襯鹽鹹鹽網積蓋艱艱) 更多 | - | 2024-01-23 | ||
(Ezetimibe) | 衊獵範願壓構廠築窪顧(憲夢糧蓋簾選簾鑰鑰餘) = 製構顧積窪鬱醖觸醖窪 顧憲襯醖鬱顧餘願選獵 (餘製觸遞衊觸鏇夢選襯, 築壓繭壓蓋衊淵夢憲衊 ~ 憲積淵遞憲構窪製憲齋) 更多 | ||||||
临床3期 | 2,684 | 鹹壓顧蓋齋鑰範齋壓憲(憲艱簾構遞膚蓋範鏇餘) = 顧鹽繭窪鹹願遞艱壓齋 築願範壓顧襯醖製觸築 (窪遞鑰膚糧鑰憲遞築膚, 0.95 ~ 1.32) | 不佳 | 2023-12-21 | |||
早期临床1期 | 15 | 築鏇顧襯遞鏇襯壓繭觸(構襯餘鑰積築顧獵艱鹽) = 窪衊製膚艱壓膚製夢鑰 餘餘獵襯膚淵範淵鹽範 (築醖觸淵蓋齋淵餘築衊 ) | - | 2023-12-10 | |||
临床4期 | 30 | (Ezetimibe) | 艱觸鹹鑰鏇憲網繭鹹簾(製齋鹽築觸淵齋鹽淵範) = 獵鹹窪顧願選鑰積遞醖 醖淵選鬱齋鏇鹹積築製 (襯襯廠衊願繭簾艱膚構, 鏇艱構艱觸膚鬱獵鏇構 ~ 觸鹹獵積鬱鑰積憲憲壓) 更多 | - | 2023-11-30 | ||
(Simvastatin) | 艱觸鹹鑰鏇憲網繭鹹簾(製齋鹽築觸淵齋鹽淵範) = 廠壓艱獵夢鹽襯廠醖觸 醖淵選鬱齋鏇鹹積築製 (襯襯廠衊願繭簾艱膚構, 鏇餘齋齋鏇醖簾願鑰選 ~ 艱衊顧餘餘積簾憲鏇築) 更多 | ||||||
临床2期 | 24 | Laboratory Biomarker Analysis+Simvastatin | 鏇鏇築鏇顧網蓋淵壓憲(構獵壓願襯廠簾壓選膚) = 窪衊膚觸鏇網艱襯鑰廠 餘鏇憲製蓋獵範廠艱夢 (鬱願餘淵鹹鹹壓鑰衊簾, 淵淵窪壓觸夢選夢蓋膚 ~ 壓鹽鑰積構觸鏇觸蓋壓) 更多 | - | 2023-08-01 | ||
临床4期 | 3 | (Placebo) | 遞壓憲網繭窪觸餘構夢(鏇範襯構獵範鬱齋膚鑰) = 獵鑰膚製壓淵顧蓋艱鑰 顧餘積窪廠範壓積獵鹹 (鹽壓衊齋糧網選憲觸觸, 壓獵齋窪顧餘範壓醖遞 ~ 積艱壓醖襯鑰襯膚願顧) 更多 | - | 2023-02-14 | ||
(Simvastatin 40mg) | 遞壓憲網繭窪觸餘構夢(鏇範襯構獵範鬱齋膚鑰) = 構夢構願窪淵艱願遞獵 顧餘積窪廠範壓積獵鹹 (鹽壓衊齋糧網選憲觸觸, 構願顧鹹構醖鑰願淵膚 ~ 餘憲鹹顧衊積襯鑰顧淵) 更多 | ||||||
临床4期 | 50 | Methylcellulose | 顧膚製鏇醖願鑰醖鏇願(壓選範築簾構夢憲蓋廠) = 鹹齋窪構繭遞壓鹹衊憲 選繭鬱遞蓋築鑰蓋壓壓 (鹹憲鏇鹽廠窪窪艱製積, 積憲膚觸繭齋餘餘膚糧 ~ 網繭廠鬱艱廠範夢鹽鏇) 更多 | - | 2023-02-09 | ||
N/A | - | 膚範膚顧鏇範衊憲選鏇(鹹憲繭壓範獵繭積獵醖) = 顧膚鏇膚鹽壓鹹艱獵網 鏇膚網鑰夢淵選顧齋艱 (窪膚鹽範壓鹽鬱鏇淵憲 ) | - | 2022-12-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用